Tumor microenvironment and myeloid-derived suppressor cells

Cancer Microenvironment

Volumn 6, Issue 2, 2013, Pages 169-177

  Umansky, Viktor ^a,b   Sevko, Alexandra ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Chronic inflammatory factors; Immunosuppression; Myeloid derived suppressor cells; Tumor microenvironment; Tumorigenesis

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR2; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PACLITAXEL; PHOSPHODIESTERASE V INHIBITOR; RETINOIC ACID; SILDENAFIL; SUNITINIB; TADALAFIL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84880920680     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-012-0126-7     Document Type: Article

References (119)

1. Ramirez-Montagut T, Turk MJ, Wolchok JD et al (2003) Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 22:3180-3187 (Pubitemid 36713770)
2. Driessens G, Kline J, Gajewski TF (2009) Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 229:126-144
3. Fridman WH, Pagès F, Sautès-Fridman C et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298-306
4. Mlecnik B, Bindea G, Pagès F et al (2011) Tumor immunosurveillance in human cancers. Cancer Metastasis Rev 30:5-12
5. Gooden MJ, de Bock GH, Leffers N et al (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93-103
6. Klebanoff CA, Acquavella N, Yu Z et al (2011) Therapeutic cancer vaccines: are we there yet? Immunol Rev 239:27-44
7. van der Bruggen P, Van den Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18:98-104 (Pubitemid 43049655)
8. Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8:577-585
9. Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494
10. Garrido F, Algarra I, García-Lora AM (2010) The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. Cancer Immunol Immunother 59:1601-1606
11. Seliger B (2012) Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 61:249-254
12. Rivoltini L, Canese P, Huber V et al (2005) Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5:463-476 (Pubitemid 40593331)
13. Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25:323-331 (Pubitemid 44922353)
14. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:11-18 (Pubitemid 351694442)
15. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:5256-5261 (Pubitemid 47510348)
16. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767
17. Sica A, Larghi P, Mancino A et al (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18:349-355
18. Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67:8429-8432 (Pubitemid 47437413)
19. Fridlender ZG, Sun J, Kim S et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16:183-194
20. Shurin MR, Naiditch H, Zhong H, Shurin GV (2011) Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 11:988-992
21. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253-268
22. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-1600
23. Young PP, Ardestani S, Li B (2010) Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression. Cancer Microenviron 4:1-11
24. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182:4499-4506
25. Baniyash M (2006) Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 16:80-88 (Pubitemid 43139712)
26. Condamine T, Gabrilovich DI (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32:19-25
27. Marigo I, Dolcetti L, Serafini P et al (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222:162-179 (Pubitemid 351430364)
28. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174
29. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969-2975
30. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE et al (2012) Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35:107-115
31. Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61:255-263
32. Wu L, Yan C, Czader M et al (2012) Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119:115-126
33. Sonda N, Chioda M, Zilio S et al (2011) Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 23:279-285
34. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2:907-916 (Pubitemid 32976162)
35. Molon B, Ugel S, Del Pozzo F (2011) Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208:1949-1962
36. Li H, Han Y, Guo Q et al (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182:240-249
37. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5:641-654 (Pubitemid 41113195)
38. Rodríguez PC, Ochoa AC (2006) T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 16:66-72 (Pubitemid 43139710)
39. Srivastava MK, Sinha P, Clements VK et al (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68-77
40. Hanson EM, Clements VK, Sinha P et al (2009) Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 183:937-944
41. Ezernitchi AV, Vaknin I, Cohen-Daniel L et al (2006) TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 177:4763-4772 (Pubitemid 44469811)
42. Rodríguez PC, Zea AH, Culotta KS et al (2002) Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 277:21123-21129 (Pubitemid 34952247)
43. Sebens Müerköster S, Werbing V, Sipos B et al (2007) Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26:2759-2768 (Pubitemid 46663831)
44. Tartour E, Pere H, Maillere B et al (2011) Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 30:83-95
45. Serafini P, Mgebroff S, Noonan K et al (2008) Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68:5439-5449
46. Qu P, Yan C, Du H (2011) Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 117:4476-4489
47. Sevko A, Sade-Feldman M, Kanterman J et al. (2012) Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents anti-tumor response in melanoma. J Invest Dermatol, in press
48. Meyer C, Sevko A, Ramacher M et al (2011) Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 108:17111-17116
49. Bunt SK, Yang L, Sinha P et al (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67:10019-10026 (Pubitemid 47621253)
50. Haverkamp JM, Crist SA, Elzey BD et al (2011) In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 41:749-759
51. Mikyšková R, Indrová M, Polláková V et al (2012) Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother 35:374-384
52. Chornoguz O, Grmai L, Sinha P (2011) Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics 10:M110.002980
53. Filipazzi P, Bürdek M, Villa A et al (2012) Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 22:342-349
54. Taylor DD, Gercel-Taylor C (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 33:441-454
55. Barreda DR, Hanington PC, Belosevic M (2004) Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 28:509-554 (Pubitemid 38177451)
56. Maione P, Rossi A, Di Maio M et al (2009) Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer 66:8-14
57. Revoltella RP, Menicagli M, Campani D (2012) Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas. Cytokine 57:347-359
58. Dolcetti L, Peranzoni E, Ugel S et al (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40:22-35
59. Ribechini E, Greifenberg V, Sandwick S et al (2010) Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 199:273-281
60. Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185:2273-2284
61. Casella I, Feccia T, Chelucci C et al (2003) Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 101:1316-1323 (Pubitemid 36182501)
62. Söderberg SS, Karlsson G, Karlsson S (2009) Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. Ann N Y Acad Sci 1176:55-69
63. Johnson B, Osada T, Clay T et al (2009) Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 9:702-707
64. Ostrand-Rosenberg S, Sinha P, Beury DW et al (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22:275-281
65. Flavell RA, Sanjabi S, Wrzesinski SH et al (2010) The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 10:554-567
66. Apte RN, Voronov E (2008) Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 222:222-241 (Pubitemid 351430377)
67. Elkabets M, Ribeiro VS, Dinarello CA et al (2010) IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 40:3347-3357
68. Tu S, Bhagat G, Cui G et al (2008) Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14:408-419
69. Sinha P, Clements VK, Fulton AM et al (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67:4507-4513 (Pubitemid 46815102)
70. Eruslanov E, Daurkin I, Ortiz J et al (2010) Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol 88:39-48
71. Ledesma E, Martνnez I, Cσrdova Y et al (2004) Interleukin-1 beta (IL-1beta) induces tumor necrosis factor alpha (TNF-alpha) expression on mouse myeloid multipotent cell line 32D cl3 and inhibits their proliferation. Cytokine 26:66-72 (Pubitemid 38410885)
72. Park EJ, Kwon TK (2011) Rottlerin enhances IL-1β-induced COX-2 expression through sustained p38 MAPK activation in MDA-MB-231 human breast cancer cells. Exp Mol Med 43:669-675
73. Bunt SK, Clements VK, Hanson EM et al (2009) Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 85:996-1004
74. Gabitass RF, Annels NE, Stocken DD et al (2011) Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60:1419-1430
75. Carmi Y, Voronov E, Dotan S (2009) The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 183:4705-4714
76. Greifenberg V, Ribechini E, Rössner S et al (2009) Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 39:2865-2876
77. Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83-89
78. Mundy-Bosse BL, Young GS, Bauer T et al (2011) Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4 T cells from patients with GI malignancy. Cancer Immunol Immunother 60:1269-1279
79. Chalmin F, Ladoire S, Mignot G et al (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120:457-471
80. Sumida K, Wakita D, Narita Y et al (2012) Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur J Immunol 42:2060-2072
81. Lesokhin AM, Hohl TM, Kitano S et al (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72:876-886
82. Zollo M, Di Dato V, Spano D et al (2012) Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis 29:585-601
83. Obermajer N, Muthuswamy R, Odunsi K et al (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71:7463-7470
84. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188:21-28
85. Connolly MK, Mallen-St Clair J, Bedrosian AS et al (2010) Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J Leukoc Biol 87:713-725
86. Ichikawa M, Williams R, Wang L et al (2011) S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9:133-148
87. Sawanobori Y, Ueha S, Kurachi M et al (2008) Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111:5457-5466
88. Kato M, Takahashi M, Akhand AA et al (1998) Transgenic mouse model for skin malignant melanoma. Oncogene 17:1885-1888 (Pubitemid 28482792)
89. Lengagne R, Le Gal FA, Garcette M et al (2004) Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells. Cancer Res 15:1496-1501 (Pubitemid 38235622)
90. Umansky V, Abschuetz O, Osen W et al (2008) Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 68:9451-9458
91. Zhao F, Falk C, Osen W et al (2009) Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res 15:4382-4390
92. Whiteside TL (2004) Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865-878 (Pubitemid 39312654)
93. Boniface JD, Poschke I, Mao Y et al (2011) Tumor-dependent down-regulation of the ζ-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 131:129-139
94. Baniyash M (2004) TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 4:675-687 (Pubitemid 39223074)
95. Qu P, Du H, Li Y et al (2009) Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol 182:1648-1659
96. Ye XZ, Yu SC, Bian XW (2010) Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 37:423-430
97. Sinha P, Okoro C, Foell D et al (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666-4675
98. Kao J, Ko EC, Eisenstein S et al (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 77:12-19
99. Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514-2522
100. Ko JS, Rayman P, Ireland J et al (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526-3536
101. Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148-2157
102. Mirza N, Fishman M, Fricke I et al (2006) All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299-9307 (Pubitemid 44521152)
103. Michels T, Shurin GV, Naiditch H et al (2012) Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol 9:292-300
104. Friedman A (2007) Transcriptional control of granulocyte and monocyte development. Oncogene 26:6816-6828 (Pubitemid 47585105)
105. Song X, Ye D, Liu B et al (2009) Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity. Cancer Sci 100:334-340
106. Shurin MR, Naiditch H, Gutkin DW et al (2012) ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents. Curr Med Chem 19:1792-1803
107. Sevko A, Kremer V, Falk C et al (2012) Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol 9:275-281
108. Suzuki E, Kapoor V, Jassar AS et al (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713-6721 (Pubitemid 41339014)
109. Vincent J, Mignot G, Chalmin F et al (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70:3052-3061
110. Boelte KC, Gordy LE, Joyce S et al (2011) Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 6:e18534
111. Ghofrani HA, Osterloh IH, Grimminger F (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5:689-702 (Pubitemid 44151606)
112. Capuano G, Rigamonti N, Grioni M, Freschi M, Bellone M (2009) Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol 10:1
113. Serafini P, Meckel K, Kelso M et al (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691-2702 (Pubitemid 44833345)
114. Ugel S, Delpozzo F, Desantis G et al (2009) Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9:470-481
115. De Santo C, Serafini P, Marigo I et al (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 102:4185-4190 (Pubitemid 40388577)
116. Jayaraman P, Parikh F, Lopez-Rivera E et al (2012) Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol 188:5365-5376
117. Veltman JD, Lambers ME, van Nimwegen M et al (2010) COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10:464
118. Fujita M, Kohanbash G, Fellows-Mayle W et al (2011) COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71:2664-2674
119. Ochoa AC, Zea A, Hernandez C (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13:721s-726s